|
|
||||||||||
Chief Resident, Internal Medicine, Cochin Hospital, Paris, France
Resident, Internal Medicine, Cochin Hospital
Assistant, Pharmacovigilance Centre, Cochin-Saint Vincent de Paul Hospital, Paris
Resident, Internal Medicine, Cochin Hospital
Resident, Internal Medicine, Cochin Hospital
Assistant, Internal Medicine, Cochin Hospital
Reprints: Florence Rollot MD, Internal Medicine, Cochin Hospital, Paris 75014, France, fax 33 1 58 41 20 80, florence.rollot{at}cch.ap-hop-paris.fr
OBJECTIVE: To report a case of colchicine intoxication occurring with institution of clarithromycin.
CASE SUMMARY: A 76-year-old man with familial Mediterranean fever (FMF) had received colchicine 1.5 mg daily for 6 years. The patient underwent 7 days of clarithromycin, amoxicillin, and omeprazole treatment for Helicobacter pyloriassociated gastritis. Fever, abdominal pain, and diarrhea occurred 3 days after treatment initiation. On day 8, dehydration, pancytopenia, metabolic acidosis, and increased lipase level necessitated hospitalization. Alopecia was observed 2 weeks later. The patient recovered fully after the colchicine dosage was reduced to 0.5 mg/day and rehydration was performed. The previous dosage was then reinstituted without adverse reaction. An objective causality assessment revealed that the adverse event was probable.
DISCUSSION: Continuous colchicine administration is used in treatment of microcrystalline arthritis, Behçet's disease, and FMF. Colchicine is primarily eliminated through biliary excretion. Renal elimination and cytochrome P450 metabolism play a less significant role. Colchicine is also a substrate of P-glycoprotein, a transporter involved in cellular efflux and elimination of numerous drugs. Three cases of intoxication have been reported when colchicine was combined with erythromycin, josamycin, or clarithromycin. Macrolides are inhibitors of P-glycoprotein and cytochrome P450dependent enzymes and may decrease colchicine's biliary excretion through P-glycoprotein inhibition.
CONCLUSIONS: Coadministration of colchicine and macrolides may impair colchicine elimination, resulting in excess drug exposure and toxicity. To this end, colchicine should be used with extreme caution in patients receiving P-glycoprotein inhibitors, particularly if they are elderly and/or renally compromised.
Key Words: clarithromycin, colchicine, P-glycoprotein
Published Online, October 19, 2004. www.theannals.com, DOI 10.1345/aph.1E197
This article has been cited by other articles:
![]() |
T. Kallinich, D. Haffner, T. Niehues, K. Huss, E. Lainka, U. Neudorf, C. Schaefer, S. Stojanov, C. Timmann, R. Keitzer, et al. Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement Pediatrics, February 1, 2007; 119(2): e474 - e483. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J. Clin. Pharmacol., November 1, 2006; 46(11): 1268 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brucato, Y. Adler, D. H. Spodick, M. Imazio, E. Cecchi, D. Demarie, B. Demichelis, F. Pomari, M. Moratti, G. Gaschino, et al. Letter Regarding Article by Imazio et al, "Colchicine in Addition to Conventional Therapy for Acute Pericarditis" * Response Circulation, April 11, 2006; 113(14): e693 - e694. [Full Text] [PDF] |
||||